

Monogenic Forms of Diabetes

Molecular mechanisms • classification • clinicopathologic interpretation

Single-gene mechanisms

β-cell secretion

Insulin action


Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraisakhri.com


Learning objectives

- Distinguish genetic defects in insulin secretion from defects in insulin action.
- Explain GCK-, transcription factor-, KATP channel-, and receptor-related mechanisms.
- Recognize genotype-directed diagnostic and therapeutic implications.




One biochemical endpoint; Different diseases

- Persistent hyperglycemia is the shared phenotype of diabetes.
- The underlying defect may be absent insulin, inadequate secretion, or impaired insulin response.
- A molecular diagnosis can therefore refine a purely clinical label.



Monogenic diabetes is not simply “young-onset diabetes”

- A single-gene lesion gives rise to a recognizable pathophysiologic syndrome.
- Age at presentation is a clue, not a molecular diagnosis.
- Genetic forms are classified separately from classic type 1 and type 2 diabetes.



Where monogenic diabetes sits in the classification

- Type 1: Usually autoimmune β -cell destruction with absolute insulin deficiency.
- Type 2: Insulin resistance plus inadequate β -cell compensation.
- Monogenic: Primary genetic dysfunction of β cells or insulin signaling.


Type 1
 β -cell destruction

Type 2
Resistance + secretion

Monogenic
Single-gene defect


The two central molecular routes

- Route 1: Impaired β -cell mass, glucose sensing, insulin synthesis, or secretion.
- Route 2: Impaired insulin receptor synthesis, ligand binding, or kinase signaling.
- Both routes can elevate circulating glucose through different proximate defects.




Why molecular subclassification matters

- Phenotypically similar cases may have different natural histories.
- In GCK-MODY, chronic hyperglycemia is generally mild and stable.
- Several other monogenic forms require ongoing risk assessment and genotype-specific therapy.




Normal β -cell physiology supplies the causal map

- Glucose enters the β cell independently of insulin.
- Glucose metabolism changes intracellular ATP availability.
- Electrical activity and Ca^{2+} influx couple glucose sensing to insulin release.




Insulin and C-peptide arise from one precursor

- Proinsulin undergoes proteolytic processing in secretory compartments.
- Mature insulin and C-peptide are released in equimolar quantities.
- C-peptide provides a measure of endogenous insulin secretion.




Glucose entry is only the first step

- GLUT2-mediated transport permits glucose entry into β cells model.
- Intracellular metabolism transduces the extracellular glucose signal.
- GCK mutations perturb the glucose-sensing threshold upstream of secretion.




ATP-sensitive potassium channels link metabolism to voltage

- A rise in intracellular ATP closes ATP-sensitive K⁺ channels.
- Reduced K⁺ efflux depolarizes the β -cell membrane.
- Depolarization triggers voltage-gated calcium entry.




Calcium is the immediate secretion signal

- A rise in intracellular Ca^{2+} stimulates insulin-granule exocytosis.
- The early release phase mobilizes stored insulin.
- Continued glucose stimulation recruits a later, sustained phase.




A receptor-level lesion acts downstream of secretion

- Insulin normally binds extracellular insulin-receptor α subunits.
- The β subunits contain receptor tyrosine kinase activity.
- A defective receptor can produce severe resistance despite elevated insulin.



IRS–PI3K–AKT transduces insulin signaling

- Receptor autophosphorylation initiates recruitment of IRS proteins.
- Downstream PI3-kinase and AKT regulate important metabolic responses.
- Lesions in receptor function compromise this normally anabolic response.



Secretory failure and resistance predict different insulin levels


- An inadequate secretory response can produce hyperglycemia with insufficient insulin output.
- Severe receptor resistance may coexist with compensatory hyperinsulinemia.
- Insulin and C-peptide must be interpreted relative to concurrent glycemia.

β -cell failure
Insulin inadequate

Receptor defect
Insulin often high


Genetic β -cell defects form a heterogeneous family

- Disorders affecting β -cell mass and/or insulin production.
- Some affect metabolic glucose sensing; Others affect transcriptional regulation.
- The classification also includes ion-channel and insulin-gene mechanisms.




Scope of the β -cell classification

- MODY genes listed: HNF4A, GCK, HNF1A, PDX1, HNF1B and NEUROD1.
- Additional groups: Neonatal diabetes, mitochondrial diabetes, proinsulin processing defects, and INS mutations.
- These categories are not interchangeable phenotypes.




MODY: Historical name, genetic definition

- “Maturity-onset diabetes of the young” reflects an early clinical resemblance to type 2 diabetes.
- Several MODY syndromes caused by germline loss-of-function variants.
- The pathogenic gene—not the historical acronym alone—determines the mechanism.




MODY often follows dominant inheritance

- Many common MODY syndromes show an autosomal-dominant family pattern.
- Diabetes in successive generations is a clinical clue.
- De novo variants and variable expression mean that a negative family history does not absolutely exclude it.




A classic family history is informative, not diagnostic

- Early-onset, non-autoimmune diabetes recurring across generations raises suspicion.
- A family history can also reflect polygenic type 2 diabetes.
- Use the complete phenotype and genetic testing rather than pedigree alone.




Phenotypic clues that warrant a MODY evaluation

- Diabetes in youth or early adulthood without the usual features of type 1 or type 2 diabetes.
- Negative islet autoantibodies and retained endogenous insulin secretion.
- Stable mild fasting hyperglycemia or diabetes across successive generations.




C-peptide answers a functional question

- C-peptide reflects endogenous β -cell secretion.
- Persisting C-peptide after diagnosis may argue against severe insulin deficiency.
- C-peptide alone does not identify a particular monogenic subtype.




Genetic testing establishes the molecular subtype

- Select testing from the clinical phenotype and family history.
- A multigene panel can examine genetically heterogeneous MODY syndromes.
- Testing strategy should also consider deletions/duplications and uncertain variants.




A sequence variant is not automatically a diagnosis

- Interpret pathogenicity, zygosity, inheritance, and clinical concordance.
- Variants of uncertain significance do not establish a molecular diagnosis on their own.
- Genetics expertise can integrate laboratory results with phenotype and counseling.



GCK acts as a β -cell glucose sensor

- Glucokinase catalyzes a rate-limiting step in oxidative glucose metabolism.
- The metabolic signal helps determine when insulin secretion increases.
- Loss-of-function variants shift the glycemic threshold required for secretion.



GCK-MODY changes the glucose “set point”


- The β cell responds as though ambient glucose were lower than it actually is.
- Insulin secretion is initiated at a higher glucose concentration.
- A stable elevation of fasting glucose follows from this recalibrated threshold.

Normal threshold

GCK higher threshold


The characteristic GCK phenotype is stable

- Typically mild, persistent fasting hyperglycemia from early life.
- Glucose levels often change relatively little over time.
- Identification frequently occurs incidentally, including in pregnancy or family testing.




GCK-MODY differs in complication risk

- Typical diabetes complications do not appear to develop in these patients.
- 2026 ADA describes microvascular complications as rare.
- This should not be generalized to HNF1A- or HNF4A-associated diabetes.



GCK-MODY treatment is often unnecessary outside pregnancy

- 2026 ADA: Most nonpregnant individuals with GCK-MODY do not need glucose-lowering treatment.
- Management depends on correct molecular identification rather than glucose value alone.
- Pregnancy requires a distinct assessment; The usual rule must not be applied uncritically.



GCK-MODY is not progressive MODY in disguise


- GCK primarily alters glucose sensing, producing a stable threshold shift.
- HNF1A/HNF4A syndromes are typically progressive secretory disorders.
- The mechanism explains why clinical trajectories diverge.

GCK
Stable set point

HNF1A / HNF4A
Progressive secretion loss


HNF1A-MODY: Progressive secretory dysfunction

- HNF1A is a transcription-factor gene in the Robbins MODY classification.
- The clinical phenotype commonly emerges in adolescence or early adulthood.
- β -cell secretory function tends to deteriorate, yielding progressive hyperglycemia.




HNF1A-MODY can produce disproportionate glycosuria

- A lower renal threshold for urinary glucose excretion is characteristic.
- Glycosuria may appear at glucose concentrations lower than expected.
- This clue has diagnostic value only within the wider phenotype.




HNF1A-MODY often has a marked oral glucose response

- The oral glucose tolerance test may show a large rise in 2-hour plasma glucose.
- Marked postchallenge hyperglycemia can precede severe fasting abnormalities.
- A dynamic phenotype contrasts with the smaller increments typical of GCK-MODY.




HNF1A-MODY is treatment-responsive to sulfonylureas

- 2026 ADA identifies sensitivity to sulfonylurea therapy.
- This represents a genotype-dependent therapeutic distinction.
- Management still requires individual assessment and hypoglycemia awareness.



HNF4A-MODY: Related progressive β -cell disease

- HNF4A is another transcription-factor gene Table 24.6.
- It produces a progressive insulin secretory defect.
- Clinical diabetes may emerge in adolescence or adulthood.



HNF4A links a neonatal phenotype to later diabetes


- Some affected infants have macrosomia and transient neonatal hypoglycemia.
- Later life may be marked by impaired insulin secretion and diabetes.
- The phenotype changes with developmental stage; It is not contradictory.

Neonatal period
Hyperinsulinemia possible

Later life
Diabetes


HNF4A-MODY may also respond to sulfonylureas

- HNF4A-associated diabetes is often sulfonylurea-sensitive.
- This overlaps therapeutically with HNF1A-MODY.
- Gene identification remains important because associated extraglycemic features differ.




HNF1B-MODY extends beyond the pancreatic islet

- HNF1B is listed as MODY5 Table 24.6.
- The phenotype includes developmental kidney disease and diabetes.
- Extrapancreatic findings can be more conspicuous than hyperglycemia.




Renal clues are prominent in HNF1B disease

- Renal cysts, hypoplasia, or other structural abnormalities may precede diabetes.
- Renal magnesium wasting and hyperuricemia may also occur.
- Unexplained kidney disease with diabetes warrants HNF1B consideration.



HNF1B has additional developmental associations

- Pancreatic atrophy can contribute to impaired insulin secretion.
- Genitourinary abnormalities and abnormal liver tests may coexist.
- Deletions encompassing HNF1B may affect neighboring genes and alter phenotype.



PDX1 and NEUROD1 are additional MODY genes

- Robbins Table 24.6 designates PDX1 as MODY4.
- The same table designates NEUROD1 as MODY6.
- These genes establish genetic diversity beyond the common GCK/HNF subtypes.

PDX1 → MODY4

NEUROD1 → MODY6

MODY names should be paired with gene symbols

- MODY1 corresponds to HNF4A; MODY2 to GCK; MODY3 to HNF1A.
- MODY4 corresponds to PDX1; MODY5 to HNF1B; MODY6 to NEUROD1.
- Use the gene designation to avoid conflating clinically different disorders.

MODY1 / 2 / 3

**HNF4A / GCK
/ HNF1A**

MODY4 / 5 / 6

**PDX1 / HNF1B
/ NEUROD1**

The four major MODY phenotypes are clinically separable

- GCK: Stable mild hyperglycemia with low typical complication burden.
- HNF1A/HNF4A: Progressive secretory dysfunction and sulfonylurea sensitivity.
- HNF1B: Renal/developmental disease in addition to diabetes.


GCK
Set point

HNF1A / HNF4A
Progressive

HNF1B
Multisystem


Neonatal diabetes is a separate monogenic presentation

- Diagnosis before 6 months of age warrants genetic evaluation independent of current age.
- 2026 ADA notes that monogenic causes account for most diabetes in this window.
- Neonatal diabetes may be permanent or transient.




KATP channels integrate metabolic and electrical signals

- The pancreatic KATP channel contains Kir6.2 and SUR1 components.
- KCNJ11 encodes Kir6.2; ABCC8 encodes SUR1.
- Activating variants can impair closure of the channel and insulin release.




How KATP activation impedes insulin release

- Excess channel opening preserves K^+ efflux despite rising metabolic ATP.
- β -cell depolarization and Ca^{2+} influx are impaired.
- The result is deficient stimulus–secretion coupling.




KCNJ11-related permanent neonatal diabetes

- Activating KCNJ11 variants are an established cause of permanent neonatal diabetes.
- Extra-pancreatic manifestations can include developmental delay or seizures.
- Some affected patients respond to oral sulfonylureas rather than continued insulin.




ABCC8-related permanent neonatal diabetes

- ABCC8 encodes the SUR1 channel subunit.
- Activating variants can result in neonatal insulin secretory failure.
- Genotype-directed sulfonylurea treatment may be effective in suitable cases.



Sulfonylureas exploit the channel mechanism

- Sulfonylureas act through the SUR1-containing KATP channel complex.
- Appropriate KATP-variant disease may permit successful treatment without injected insulin.
- Any transition should occur under specialist supervision, not from a slide algorithm alone.



Not all permanent neonatal diabetes is KATP-mediated


- INS variants can impair insulin biosynthesis and cause permanent neonatal diabetes.
- 2026 ADA lists insulin treatment as the preferred strategy for INS-related neonatal diabetes.
- Different genes may produce the same neonatal presentation but require different treatment.

**KATP-related
Sulfonylurea possible**

**INS-related
Insulin generally needed**


Transient neonatal diabetes has other mechanisms

- 2026 ADA includes abnormal regulation at chromosome 6q24 among transient causes.
- The disease can remit in infancy and recur later.
- A molecular classification is necessary even when early hyperglycemia resolves.




Neonatal diagnosis is an age-triggered genetic problem

- First question: Was diabetes diagnosed in the first six months of life?
- If yes, evaluate genetically regardless of later clinical status.
- The result informs counseling and whether channel-targeted therapy is possible.




Mitochondrial diabetes is a different inheritance model

- Maternally inherited diabetes and deafness (MIDD).
- The implicated variants are in mitochondrial DNA rather than a nuclear MODY gene.
- Associated hearing loss may guide evaluation of diabetes across maternal relatives.




Defective proinsulin conversion is also classified separately

- The β cell normally processes proinsulin into mature insulin and C-peptide.
- Defects in proinsulin conversion among monogenic β -cell disorders.
- This mechanism is distinct from defective glucose sensing or receptor signaling.




INS mutations alter insulin production directly

- Robbins recognizes insulin gene mutations as monogenic causes of diabetes.
- These lesions affect the hormone-producing machinery itself.
- The same gene category is clinically relevant to some cases of permanent neonatal diabetes.




Insulin receptor defects cause extreme resistance

- Mutations may reduce receptor synthesis, insulin binding, or receptor tyrosine kinase activity.
- A severe reduction in insulin action may occur despite high circulating insulin.
- This phenotype as type A insulin resistance.




Type A insulin resistance: Phenotype follows mechanism

- Disproportionate insulin resistance is the primary abnormality.
- Hyperinsulinemia reflects compensation for inadequate target-cell signaling.
- Hyperglycemia develops when compensation is insufficient.



Acanthosis nigricans is a clinical clue

- Velvety cutaneous hyperpigmentation in type A insulin resistance.
- Acanthosis nigricans is not genetically specific on its own.
- Its significance increases in the context of unusually severe resistance.



Additional endocrine features may accompany type A resistance

- Polycystic ovaries in affected females.
- Elevated androgen concentrations can coexist.
- The combination reflects severe insulin action impairment but is not diagnostic by itself.

Acanthosis

Hyperandrogenism

Severe resistance

Lipoatrophic diabetes belongs in the insulin-action group


- Robbins Table 24.6 places lipoatrophic diabetes under genetic defects in insulin action.
- This categorization differs from the primary β -cell secretion group.
- The classification illustrates that monogenic diabetes extends beyond MODY.

Primary secretion defect

Insulin-action disorder

A mechanistic differential can start with two questions

- Is insulin secretion appropriately matched to glycemia?
- Is insulin resistance disproportionate to the clinical context?
- A specific genetic result refines the branch-level hypothesis.



Type 1, type 2 and monogenic disease can look alike

- Type 1 commonly has islet autoantibodies and progressive absolute insulin deficiency.
- Type 2 commonly involves obesity-associated resistance plus β -cell dysfunction.
- Monogenic disease should be considered when age, autoantibodies, insulin output and family history do not fit.

**Type 1
Autoimmune**

**Type 2
Multifactorial**

**Monogenic
Pathogenic variant**

Common diagnostic shortcuts can misclassify patients

- Youth does not automatically establish type 1 diabetes.
- Absence of obesity does not prove MODY; Obesity does not exclude it.
- A negative antibody result is a clue, not a pathogenic variant.


**Avoid age
shortcut**

**Avoid BMI
shortcut**

**Confirm
molecularly**


Case: Stable hyperglycemia across three generations

- A lean 17-year-old and two first-degree relatives have longstanding mild fasting hyperglycemia.
- None has progressive insulin requirement or typical diabetes complications.
- The mechanism most consistent with this pattern is a raised GCK glucose threshold.




Case: Progressive diabetes with unusual glycosuria

- A young adult has progressive hyperglycemia with preserved C-peptide and negative islet antibodies.
- Glucosuria is conspicuous at modest plasma glucose concentrations.
- HNF1A-MODY is a reasonable molecular hypothesis; Confirm by genetic testing.




Case: Diabetes accompanied by renal cysts

- A patient has early-onset diabetes plus congenital renal cystic changes.
- The phenotype involves development of organs outside the islet.
- HNF1B is the key gene to consider, while retaining a broader differential.




Case: Diabetes diagnosed at eight weeks

- An infant requires insulin treatment for marked hyperglycemia.
- Diagnosis under six months mandates consideration of neonatal diabetes genetics.
- KCNJ11, ABCC8 and INS are relevant genes; Test before assuming a treatment mechanism.



Case: Severe resistance despite high insulin

- A young person has acanthosis nigricans, very high insulin, and hyperglycemia.
- The primary deficit may lie at the insulin receptor rather than insulin production.
- A targeted assessment for type A insulin resistance is appropriate.



Why tissue microscopy is not the primary classifier

- These diseases are fundamentally molecular and functional rather than defined by a characteristic routine biopsy pattern.
- Glucose sensing, hormone synthesis, and receptor signaling cannot be diagnosed by nonspecific islet morphology alone.
- Biochemical phenotype plus verified molecular testing is more discriminating.

Functional phenotype

Genetics

Not routine histology

Clinical utility follows the causal gene

- GCK: Distinguish stable threshold hyperglycemia from progressive diabetes.
- HNF1A/HNF4A and selected KATP defects: Consider genotype-directed therapy.
- HNF1B or MIDD: Actively recognize associated non-glycemic findings.

Diagnosis

**Therapeutic
response**

**Family / organ
screening**

A compact mechanism-based synthesis

- β -cell transcription/metabolism genes explain many MODY phenotypes.
- KATP channel and INS disorders explain important neonatal presentations.
- Insulin receptor defects illustrate monogenic severe insulin resistance.

**MODY
 β -cell function**

**Neonatal
Channel / insulin**

**Type A
Insulin receptor**

Selected references

- Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Chapter 24; Table 24.6.
- American Diabetes Association. Standards of Care in Diabetes—2026. Section 2: Diagnosis and Classification.
- Naylor R, et al. Maturity-Onset Diabetes of the Young Overview. GeneReviews, NCBI Bookshelf.

**Textbook
framework**

**2026 clinical
criteria**

**Genetic
phenotype
detail**